Momelotinib Effectiveness in Myelofibrosis
ConditionMyelofibrosis (MF)
Trial statusNot yet recruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18+
SponsorGruppo Italiano Malattie EMatologiche dell'Adulto
About this trial
Observational study aimed at evaluating the use of momelotinib in patients with primary or post polycythemia vera (PV) or post essential thrombocythemia myelofibrosis (post-ET MF) in a real-world setting.
Eligibility criteria
Qualifiers
Patients aged 18 years or older.
Patients diagnosed with primary or post-polycythemia vera/post-essential thrombocythemia myelofibrosis start treatment with MMB according to clinical practice from AIFA authorization.
Patients with palpable splenomegaly at baseline of momelotinib treatment.
Informed consent signed, if applicable.
Disqualifiers
Diagnosis of MPN, unclassifiable, myelodysplastic/myeloproliferative neoplasms, myelodysplastic syndromes, essential thrombocythemia, polycythemia vera.
Accelerated/blast phase of MF.
Patients with platelets <20 x10(9)/L at baseline of MMB treatment.
Patients JAK inhibitors-exposed for other diseases apart from MF.
Trial design
Treatments tested in this trial
- Not listed
Trial groups
93 Participants
are grouped into 1 trial groupLocations
Sponsors and collaborators
Source ClinicalTrials.gov